We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
52 hedge funds and large institutions have $44.6M invested in Corvus Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
136% more capital invested
Capital invested by funds: $18.9M → $44.6M (+$25.7M)
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
41% more funds holding
Funds holding: 37 → 52 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less call options, than puts
Call options by funds: $266K | Put options by funds: $272K
2.79% less ownership
Funds ownership: 44.65% → 41.86% (-2.8%)
Holders
52
Holders Change
+15
Holders Change %
+40.54%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
22
Increased
11
Reduced
6
Closed
7
Calls
$266K
Puts
$272K
Net Calls
-$6K
Net Calls Change
-$15K
Top Buyers
| 1 |
SC
Samlyn Capital
New York
|
+$4.38M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$621K |
| 3 |
TL
TowerView LLC
New York
|
+$426K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$384K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
+$208K |
